Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ferric carboxymaltose
Drug ID BADD_D00882
Description Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.
Indications and Usage Ferric carboxymaltose is a iron replacement product indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron or those who have non-dialysis dependent chronic kidney disease.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB08917
KEGG ID D08920
MeSH ID C522335
PubChem ID 86278165
TTD Drug ID D02ICI
NDC Product Code 64552-4070; 42973-330; 59353-363; 0517-0620; 14593-923
UNII 6897GXD6OE
Synonyms ferric carboxymaltose | iron carboxymaltose | iron dextri-maltose | polynuclear iron (III)-hydroxide 4(R)-(poly-(1->4)-o-alpha-D-glucopyranosyl)-oxy-2(R),3(S),5(R), 6-tetrahydroxy-hexanoate | Ferinject | VIT-45 | VIT 45 | injectafer
Chemical Information
Molecular Formula C24H44FeO25-
CAS Registry Number 9007-72-1
SMILES C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)OC(C(CO)O)C(C(C(=O)[O-])O)O)CO)CO )O)O)O)O.O.[OH-].[O-2].[Fe+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Alanine aminotransferase increased13.03.04.005--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Arthralgia15.01.02.001--
Back pain15.03.04.005--
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.009--Not Available
Chills15.05.03.016; 08.01.09.001--
Constipation07.02.02.001--
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Erythema23.03.06.001--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gamma-glutamyltransferase increased13.03.04.024--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Injection site irritation12.07.03.027; 08.02.03.027--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Nausea07.01.07.001--
Paraesthesia23.03.03.094; 17.02.06.005--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Sneezing22.12.03.024--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Urticaria23.04.02.001; 10.01.06.001--
The 1th Page    1 2    Next   Last    Total 2 Pages